{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:46:30Z","timestamp":1779212790048,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate the optimal blood pressure (BP) in patients with coronary artery disease (CAD), we conducted subgroup analysis using SPRINT data. The study sample included 1206 participants with CAD (of whom 692 underwent coronary revascularization) and 8127 participants without CAD. Participants were randomized into two groups (systolic BP target of 140\u2009mm\u2009Hg vs. 120\u2009mm\u2009Hg). The primary outcome was a composite of cardiovascular events. After a median follow-up of 3.9 years, the hazard ratios (HRs) for the primary outcome were 0.65 (95% confidence interval (CI) 0.53\u20130.79) and 1.05 (95% CI 0.76\u20131.46) among those in the non-CAD and CAD subgroups, respectively (<jats:italic>P<\/jats:italic> value for interaction 0.02). Intensive BP treatment was a protective factor for all-cause death (HR 0.60, 95% CI 0.37\u20130.96) in the CAD subgroup, compared with standard BP treatment. The HRs (95% CI) for stroke were 3.57 (1.17\u201310.85) and 1.03 (0.29\u20133.62) among those in the coronary revascularization and non-revascularization subgroups, respectively (<jats:italic>P<\/jats:italic> value for interaction 0.13). For safety events, intensive BP treatment increased the risk of hypotension (HR 2.00, 95% CI 1.06\u20133.79) and electrolyte abnormalities (HR 2.38, 95% CI 1.25\u20134.56) in the CAD subgroup, while the risk of serious adverse events did not increase (HR 1.03, 95% CI 0.88\u20131.20). These results suggest that positive benefits from intensive BP treatment might be attenuated in patients with CAD who are under better secondary prevention. The risk of stroke might increase at the systolic BP target of 120\u2009mm\u2009Hg in case of coronary revascularization, although the confidence interval was wide.<\/jats:p>","DOI":"10.1038\/s41371-021-00494-8","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T16:55:41Z","timestamp":1613580941000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT)"],"prefix":"10.1038","volume":"36","author":[{"given":"Jiabin","family":"Zang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-8507","authenticated-orcid":false,"given":"Xiaodong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaozhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-1866","authenticated-orcid":false,"given":"Xinxue","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-6643","authenticated-orcid":false,"given":"Guifu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"494_CR1","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/archinte.1993.00410050036006","volume":"153","author":"J Stamler","year":"1993","unstructured":"Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. Us population data. Arch Intern Med. 1993;153:598\u2013615.","journal-title":"Arch Intern Med."},{"key":"494_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet."},{"key":"494_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"MH Forouzanfar","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990\u20132015. JAMA. 2017;317:165\u201382.","journal-title":"JAMA."},{"key":"494_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamainternmed.2016.0190","volume":"176","author":"S Lewington","year":"2016","unstructured":"Lewington S, Lacey B, Clarke R, Guo Y, Kong XL, Yang L, et al. The burden of hypertension and associated risk for cardiovascular mortality in china. JAMA Intern Med. 2016;176:524\u201332.","journal-title":"JAMA Intern Med."},{"key":"494_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14779072.2018.1534069","volume":"16","author":"D Mahtta","year":"2018","unstructured":"Mahtta D, Elgendy IY, Pepine CJ. Optimal medical treatment of hypertension in patients with coronary artery disease. Expert Rev Cardiovasc Ther. 2018;16:815\u201323.","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"494_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet."},{"key":"494_CR7","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Prim. 2018;4:18014.","journal-title":"Nat Rev Dis Prim."},{"key":"494_CR8","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APHA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71:e13\u2013e115.","journal-title":"Hypertension."},{"key":"494_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/bmj.297.6658.1227","volume":"297","author":"JM Cruickshank","year":"1998","unstructured":"Cruickshank JM. Coronary flow reserve and the j curve relation between diastolic blood pressure and myocardial infarction. BMJ. 1998;297:1227\u201330.","journal-title":"BMJ."},{"key":"494_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11883-017-0670-1","volume":"19","author":"F Rahman","year":"2017","unstructured":"Rahman F, McEvoy JW. The j-shaped curve for blood pressure and cardiovascular disease risk: historical context and recent updates. Curr Atheroscler Rep. 2017;19:34.","journal-title":"Curr Atheroscler Rep."},{"key":"494_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/08037051.2015.1106750","volume":"25","author":"SE Kjeldsen","year":"2016","unstructured":"Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, et al. No evidence for a j-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25:83\u201392.","journal-title":"Blood Press."},{"key":"494_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejim.2017.08.029","volume":"48","author":"C Di Nora","year":"2018","unstructured":"Di Nora C, Cioffi G, Iorio A, Rivetti L, Poli S, Zambon E, et al. Systolic blood pressure target in systemic arterial hypertension: Is lower ever better? Results from a community-based caucasian cohort. Eur J Intern Med. 2018;48:57\u201363.","journal-title":"Eur J Intern Med."},{"key":"494_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"FH Messerli","year":"2006","unstructured":"Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884\u201393.","journal-title":"Ann Intern Med."},{"key":"494_CR14","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl J Med. 2015;373:2103\u201316.","journal-title":"N. Engl J Med."},{"key":"494_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/2047487318800741","volume":"26","author":"A Attar","year":"2019","unstructured":"Attar A, Sayadi M, Jannati M. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial. Eur J Prev Cardiol. 2019;26:238\u201345.","journal-title":"Eur J Prev Cardiol."},{"key":"494_CR16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","volume":"27","author":"P Sleight","year":"2009","unstructured":"Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens. 2009;27:1360\u20139.","journal-title":"J Hypertens."},{"key":"494_CR17","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"CJ Pepine","year":"2003","unstructured":"Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805\u201316.","journal-title":"JAMA."},{"key":"494_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jacc.2014.05.044","volume":"64","author":"S Bangalore","year":"2014","unstructured":"Bangalore S, Gong Y, Cooper-DeHoff RM, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol. 2014;64:784\u201393.","journal-title":"J Am Coll Cardiol."},{"key":"494_CR19","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217\u201325.","journal-title":"JAMA."},{"key":"494_CR20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1001\/jama.292.18.2271","volume":"292","author":"CJ Pepine","year":"2004","unstructured":"Pepine CJ. What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA. 2004;292:2271\u20133.","journal-title":"JAMA."},{"key":"494_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775\u201381.","journal-title":"JAMA Cardiol."},{"key":"494_CR22","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1161\/CIRCULATIONAHA.109.905687","volume":"122","author":"S Bangalore","year":"2010","unstructured":"Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142\u201351.","journal-title":"Circulation."},{"key":"494_CR23","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1093\/eurheartj\/ehq328","volume":"31","author":"S Bangalore","year":"2010","unstructured":"Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the treating to new targets (TNT) trial. Eur Heart J. 2010;31:2897\u2013908.","journal-title":"Eur Heart J."},{"key":"494_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","volume":"68","author":"JW McEvoy","year":"2016","unstructured":"McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713\u201322.","journal-title":"J Am Coll Cardiol."},{"key":"494_CR25","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","volume":"389","author":"M B\u00f6hm","year":"2018","unstructured":"B\u00f6hm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2018;389:2226\u201337.","journal-title":"Lancet."},{"key":"494_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(94)91459-1","volume":"343","author":"JC Witteman","year":"1994","unstructured":"Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Burger H, et al. J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet. 1994;343:504\u20137.","journal-title":"Lancet."},{"key":"494_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00395-017-0651-0","volume":"112","author":"L Casadonte","year":"2017","unstructured":"Casadonte L, Verhoeff BJ, Piek JJ, VanBavel E, Spaan JAE, Siebes M. Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity. Basic Res Cardiol. 2017;112:61.","journal-title":"Basic Res Cardiol."},{"key":"494_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.amjmed.2018.05.022","volume":"131","author":"TC Lee","year":"2018","unstructured":"Lee TC, Cavalcanti RB, McDonald EG, Pilote L, Brophy JM. Diastolic hypotension may attenuate benefits from intensive systolic targets: secondary analysis of a randomized controlled trial. Am J Med. 2018;131:1228\u201333.e1.","journal-title":"Am J Med."},{"key":"494_CR29","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41440-019-0287-6","volume":"42","author":"K Asayama","year":"2019","unstructured":"Asayama K, Ohkubo T, Rakugi H, Miyakawa M, Mori H, Katsuya T, et al. Comparison of blood pressure values-self-measured at home, measured at an unattended office, and measured at a conventional attended office. Hypertens Res. 2019;42:1726\u201337.","journal-title":"Hypertens Res."}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00494-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00494-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:24:35Z","timestamp":1642497875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-021-00494-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["494"],"URL":"https:\/\/doi.org\/10.1038\/s41371-021-00494-8","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}